Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
xylitol + levocarnitine
- Development stage
- Unknown
- Lead developer
- Iperboreal Pharma
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Xylocarn (xylitol + levocarnitine) is an intravenous combination therapy developed by Iperboreal Pharma for the management of complications in patients with end-stage kidney disease (ESKD) undergoing maintenance hemodialysis. The formulation combines xylitol, a five-carbon sugar alcohol, with levocarnitine (L-carnitine), an amino acid derivative essential for fatty acid metabolism. Xylitol serves as an osmotic agent to stabilize plasma osmolality and prevent intradialytic hypotension (IDH), while also providing a non-insulin-dependent energy source. Levocarnitine addresses the systemic carnitine deficiency common in dialysis patients, supporting myocardial function and energy production by facilitating the transport of long-chain fatty acids into the mitochondria. The combination is designed to be administered during the dialysis session to improve metabolic stability and reduce the incidence of blood pressure drops.
- Brand names
- Xylocarn
- Other names
- L-carnitine + xylitollevocarnitine + xylitol
02
Targets
SLC7A1 (Cationic amino acid transporter 1)
Beyond the preview
Go deeper on xylitol + levocarnitine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on xylitol + levocarnitine.